FMC Technologies, Inc. (NYSE:FTI) shares slumped $2.32 or 5.16%. The company said that it earned $121 million, or 50 cents a share on revenue of $1.29 billion, beating analysts’ estimates of 46 cents a share, while revenue fell short of analysts’ estimates marginally. FMC’s backlog fell to $4.6 billion from $5.0 billion three months before.
The company projects to generate profit of 46 cents and 51 cents in the current quarter, missing analysts’ estimates of 51 cents a share.
Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) shares soared 13.36% to $37.75 in the extended trading session after the company reported that it earned $22.9 million or $0.35 a share on revenue of $59.8 million. On an adjusted basis, the company earned 37 cents a share, topping analysts estimates of 26 cents a share on revenue of $53.42 million.
Human Genome Sciences (NASDAQ:HGSI) shares slumped $1.53 or 12.02% to $12.73 after the company said that it had a net loss of 45 cents a share on revenue of $34 million, missing analyst estimates of a loss of 39 cents a share on revenue of $37.31 million.
The Company now expects cash and investments at year-end 2011 to total between $440 million and $470 million, net of $79 million principal amount and interest paid upon maturity of the 2011 convertible debt.
The assembled information distributed by headlineotc.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Headlineotc.com does expect that investors will buy and sell securities based on information assembled and presented herein. Headlineotc.com will not be responsible in any way for or accept any liability for any losses arising from an investor’s reliance on or use of information obtained from our website or emails. PLEASE always do your own due diligence, and consult your financial advisor.